The pace of development for CRISPR-based infectious disease assays increased as the pandemic progressed, more funding became available, and collaboration accelerated.
Oncocyte will receive upfront cash payments after transferring and installing DetermaRx, in addition to certain tests after it achieves inclusion in the US Comprehensive Cancer Network.
Vivlion, which also holds a license to Goethe University Frankfurt's CRISPR technology, will use the license to offer R&D reagents and screening services.
TwinStrand's duplex sequencing correction technology can detect ultra-low frequency DNA mutations that are otherwise often obscured by technical noise.
Under the agreement, Genetron gains exclusive rights to develop and commercialize minimal residual disease assays using ImmuQuad's immunogenomics technology.
